Cytokinetics (CYTK) Other Non-Current Liabilities (2017 - 2026)
Cytokinetics (CYTK) posted quarterly Other Non-Current Liabilities of $29.6 million for Q1 2026, up 152.99% year-over-year from $11.7 million in Q1 2025, and down 4.82% quarter-over-quarter from $31.1 million in Q4 2025.
Cytokinetics (CYTK) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Other Non-Current Liabilities for 10 consecutive years, with $29.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 152.99% year-over-year to $29.6 million; the TTM figure through Mar 2026 stood at $29.6 million (up 152.99% YoY), while the FY2025 annual figure was $31.1 million, up 175.22% from the prior year.
- Other Non-Current Liabilities slipped to $29.6 million in Q1 2026 per CYTK's latest filing, from $31.1 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $104.7 million in Q2 2024 and bottomed at $408000.0 in Q3 2023.
- Historically, Other Non-Current Liabilities has averaged $14.8 million across 5 years, with a median of $7.3 million in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 99.29% — and 2024, when it jumped 16652.0%.
- Cytokinetics' Other Non-Current Liabilities stood at $1.0 million in 2022, then surged by 1106.9% to $12.6 million in 2023, then decreased by 10.32% to $11.3 million in 2024, then surged by 175.22% to $31.1 million in 2025, then declined by 4.82% to $29.6 million in 2026.
- Business Quant data shows CYTK's Other Non-Current Liabilities at $29.6 million in Q1 2026, $31.1 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.70 Mn |
| Mar 31, 2026 | 29.60 Mn |
| Dec 31, 2025 | 31.10 Mn |
| Sep 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 12.80 Mn |
| Mar 31, 2025 | 11.70 Mn |
| Dec 31, 2024 | 11.30 Mn |
| Jun 30, 2024 | 104.70 Mn |
| Mar 31, 2024 | 12.60 Mn |
| Dec 31, 2023 | 12.60 Mn |
| Sep 30, 2023 | 408,000.00 |
| Jun 30, 2023 | 625,000.00 |
| Mar 31, 2023 | 837,000.00 |
| Dec 31, 2022 | 1.04 Mn |
| Sep 30, 2022 | 1.25 Mn |
| Jun 30, 2022 | 1.44 Mn |
| Mar 31, 2022 | 3.21 Mn |
| Dec 31, 2021 | 4.46 Mn |
| Sep 30, 2021 | 174.80 Mn |
| Jun 30, 2021 | 171.79 Mn |